Australian biotechnology company AdvanCell has unveiled the first clinical results of its novel targeted alpha therapy 212Pb-ADVC001 for prostate cancer at the European Society for Medical Oncology Congress 2025, marking a significant moment in the evolution of PSMA-targeted radioligand therapy. …
AdvanCell unveils promising first clinical results for 212Pb-ADVC001 in prostate cancer
October 19, 2025 Australian Biotech
Latest Video
New Stories
-
Medicines Australia seeks answers on AI in HTA process
September 23, 2026 - - Latest News -
The prevention gap and inside Sally Panton's bet on cellular health
September 23, 2026 - - Latest News -
Pfizer 'deeply disappointed' in response to PBAC refusing to move on price
September 23, 2026 - - Latest News -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News -
A 'multistakeholder' reference group to shadow agreement negotiations
September 23, 2026 - -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News